Skip to main content
Peter MacCallum Cancer Centre
  • Donate
  • Location
  • Search
  • English
  • Easy English
  • العَرَبِيَّة Arabic
  • 中文 Chinese
  • Eλληνικά Greek
  • हिन्दी Hindi
  • Italiano Italian
  • Tagalog Tagalog
  • Türkçe Turkish
  • Tiếng Việt Vietnamese
  • About
  • Profiles
  • Careers
  • Education
  • News
  • Events
  • Get involved
  • Contact
  • Cancer types
    • Breast
    • Upper Gastrointestinal
    • Lower Gastrointestinal
    • Genitourinary Oncology
    • Gynae-oncology
    • Clinical Haematology
    • Head & neck
    • Lung
    • Melanoma & Skin
    • Neuro-oncology
    • Paediatric
    • Sarcoma
    • Cancer of unknown primary
  • Our services
    • Diagnosis & investigations
    • Treatment
    • Support services
    • Cancer information & resources
  • Coming to Peter Mac
    • Melbourne
    • Bendigo
    • Box Hill
    • Moorabbin
    • Sunshine
    • Telehealth
  • Research & discovery
    • Clinical research
    • COE in Cellular Immunotherapy
    • Research laboratories
    • Core facilities and services
    • ProsTIC
    • Research cohort studies
    • Research programs
    • Doing research with us
    • Commercialisation, partnerships and industry engagement
    • Publications
    • Research strategy
    • Education in research
    • Health Services Research
  • Clinical Trial Care
    • Patients and Families
    • Health Professionals
    • Clinical Trial Sponsors
  1. Home
  2. Profiles
  3. Prof Sherene Loi
Consultant Medical Oncologist; Group Leader; Breast Stream Lead PCCTU; National Breast Cancer Foundation of Australia Endowed Chair

Prof Sherene Loi

Medical Oncology

Biography

As head of the Translational Breast Cancer Genomics and Therapeutics Laboratory, Professor Sherene Loi's research interest is to translate interesting scientific findings into innovative treatment approaches that may ultimately improve the survival of breast cancer patients. To facilitate this, her laboratory uses genomic approaches to analyse breast cancer specimens to understand mechanisms of growth, immune evasion and progression. For patients, Prof. Loi's interest lies in clinical trials evaluating targeted agents against specific breast cancer molecular subtypes.

Being a clinician, Professor Loi has a strong focus on translation. Based on rationale from preclinical work, she developed and led the first phase II study of PD-1 inhibition (pembrolizumab) in combination with trastuzumab in the advanced HER2-positive setting. This was an international study. She was one of the first clinicians to treat advanced TNBC patients with pembrolizumab and involved (Steering committee) in protocol development and recruitmen to the first Phase III registration study of atezolizumab in advanced TNBC (Impassion130 published in the NEJM). She is leading two global registration studies in immunotherapy in breast cancer. These are the KATE3 study (advanced HER2 positive breast cancer) as well as early stage high-risk hormone receptor positive breast cancer. Additionally, Professor Loi has a number of investigator led clinical trials ongoing.

Professor Loi also has a strong interest in biomarker development as this can help us manage patients better. She has also led the development and implementation of an immune biomarker in breast cancer: tumor infiltrating lymphocytes (TILS). With pathologist collaborator, Dr Roberto Salgado, they have developed the International Immune Oncology Working Group. This biomarker is now established as part of routine breast cancer pathology reporting in many countries for prognosis as well as ultimately for use in prediction of responders to checkpoint blockade. It was also included in the 2019 WHO Blue Book on Breast Tumors as well as recommended by the European Society of Medical Oncology early breast cancer guidelines and the St Gallen early breast cancer consensus guidelines.

Professor Loi is Co-Chair of the Swiss based International Breast Cancer Study Group (IBCSG) as well as a non-Executive Director and Scientific Committee Member of Breast Cancer Trials (BCT) Australian and New Zealand breast cancer cooperative trials group. She is also a Board Member of the Breast International Group (BIG), Belgium. Professor Loi is a graduate and member of the Australian Institute of Company Directors.

In the news

Prof Sherene Loi awarded Outstanding Investigator Award for Breast Cancer Research by the American Association of Cancer Research (AACR)

Peter Mac Researchers among the world's most highly cited

TILs can indicate immune system alert to cancer and treatment outcome

New understanding of how the immune system responds to breast cancer

Related links

Loi Laboratory

Breast

@LoiSher

Awards

  • 2021 Australian Academy of Health and Medical Sciences Jian Zhou Medal recipient
  • 2020 AACR Outstanding Investigator Award for Breast Cancer Research
  • 2020 European Society of Clinical Oncology Breast Cancer Award
  • 2019 Breast Cancer Trials, Robert Sutherland Award for Excellence in Translational Research
  • 2019 Bruce Cain Orator Prize, New Zealand Society for Oncology
  • 2018 – 2020 Clarivate Analytics, Highly Cited Researcher in the field of Clinical Medicine
  • 2018 – 2022 Inaugural National Breast Cancer Research Foundation (Australia) Endowed Chair
  • 2016 Peter Mac Award in the “Accelerate Discovery” Individual Category
  • 2015-2022 Breast Cancer Research Foundation, NY Research Fellow

Qualifications

MBBS (Hons), PhD, FRACP, FAHMS, GAICD
Sherene Loi's complete list of publications

Consultant Medical Oncologist; Group Leader; Breast Stream Lead PCCTU; National Breast Cancer Foundation of Australia Endowed Chair

Prof Sherene Loi

Medical Oncology

Phone
@LoiSher

Breast

Breast cancer is a malignant tumour that starts in breast tissue of a man or woman.
Read more

Peter MacCallum Cancer Centre

  • Victorian Comprehensive Cancer Centre building
    305 Grattan Street
    Melbourne VIC 3000
    Australia
    Peter MacCallum Cancer Centre
  • (03) 8559 5000 (In an emergency, call 000)
  • (03) 8559 7379 (Main fax)
  • (03) 8559 7371 (Referrals fax)
  • Locations
    • Melbourne
    • Bendigo
    • Box Hill
    • Moorabbin
    • Sunshine
  • About us
    • Get involved
    • Upcoming events
    • Partnerships
    • Patient charter
  • Cancer types
  • Cancer services
    • Diagnosis & investigations
    • Treatments
    • Cancer info & resources
  • Refer your patient
  • Peter MacCallum Cancer Foundation
  • Australian Cancer Survivorship Centre
  • Research & discovery
    • Clinical research & trials
    • Research cohort studies
    • Research labs
  • Careers
  • Education

Our Community

  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Contact us
Comments & feedback

The Peter MacCallum Cancer Centre acknowledges the traditional owners of the land on which our five sites are located throughout Victoria. We recognise their strength and resilience and pay our respects to their Elders past and present.

Languages
Auslan
Interpreter
Site by Icon Agency
  • Privacy policy
  • Terms & Conditions
  • Intranet